AG
SGMO

Artal Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Artal Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-405,000
Closed -$3.39M – 114
2019
Q4 		$3.39M Hold
405,000
– – 0.13% 85
2019
Q3 		$3.67M Hold
405,000
– – 0.15% 83
2019
Q2 		$4.36M Buy
405,000
+5,000
+1% +$53.2K 0.18% 83
2019
Q1 		$3.82M Hold
400,000
– – 0.16% 84
2018
Q4 		$4.59M Buy
400,000
+100,000
+33% +$1.24M 0.17% 69
2018
Q3 		$5.08M Buy
300,000
+100,000
+50% +$1.52M 0.13% 75
2018
Q2 		$2.84M Buy
200,000
+50,000
+33% +$831K 0.06% 87
2018
Q1 		$2.85M Buy
+150,000
New +$3.21M 0.04% 88

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group's SGMO Position: Q1 2020 in Review

Artal Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2020, closing a stake of 405,000 shares — an estimated $3.39M sold.

Artal Group first reported a position in SGMO in Q1 2018 and held it in 8 quarters. The position peaked at $5.08M in Q3 2018. 190 funds tracked by Wall St. Rank hold SGMO as of Q1 2020.

  • Artal Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2020 after selling out during the quarter.
  • Artal Group sold 405,000 SANGAMO THERAPEUTICS INC shares in Q1 2020, an estimated $3.39M.
  • Artal Group first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 8 quarters.
  • Artal Group's SANGAMO THERAPEUTICS INC position peaked at $5.08M in Q3 2018.
  • 190 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2020.

Based on Artal Group's 13F filing for Q1 2020, filed 14 May 2020.